Payers will present their thoughts on the influence of digitisation, high-priced therapies and patient access on drug expenditures management in Germany's statutory health insurance GKV in times of the Covid-19 pandemic. What changes will come in 2020/21?
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.